cd13 receptor
Recently Published Documents


TOTAL DOCUMENTS

12
(FIVE YEARS 3)

H-INDEX

8
(FIVE YEARS 0)

2021 ◽  
Vol 2021 ◽  
pp. 1-11
Author(s):  
Adrienn Kis ◽  
Noémi Dénes ◽  
Judit P. Szabó ◽  
Viktória Arató ◽  
Lívia Beke ◽  
...  

Introduction. The aminopeptidase N (APN/CD13) receptor plays an important role in the neoangiogenic process and metastatic tumor cell invasion. Clinical and preclinical studies reported that bestatin and actinonin are cytotoxic to APN/CD13-positive tumors and metastases due to their APN/CD13-specific inhibitor properties. Our previous studies have already shown that 68Ga-labeled NGR peptides bind specifically to APN/CD13 expressing tumor cells. The APN/CD13 specificity of 68Ga-NGR radiopharmaceuticals enables the following of the efficacy of antiangiogenic therapy with APN/CD13-specific inhibitors using positron emission tomography (PET). The aim of this in vivo study was to assess the antitumor effect of bestatin and actinonin treatment in subcutaneous transplanted HT1080 and B16-F10 tumor-bearing animal models using 68Ga-NODAGA-c(NGR). Materials and Methods. Three days after the inoculation of HT1080 and B16-F10 cells, mice were treated with intraperitoneal injection of bestatin (15 mg/kg) or actinonin (5 mg/kg) for 7 days. On the 5th and 10th day, in vivo PET scans and ex vivo biodistribution studies were performed 90 min after intravenous injection of 5.5 ± 0.2   MBq 68Ga-NODAGA-c(NGR). Results. Control-untreated HT1080 and B16-F10 tumors were clearly visualized by the APN/CD13-specific 68Ga-NODAGA-c(NGR) radiopharmaceutical. The western blot analysis also confirmed the strong APN/CD13 positivity in the investigated tumors. We found significantly ( p ≤ 0.05 ) lower radiopharmaceutical uptake after bestatin treatment and higher radiotracer accumulation in the actinonin-treated HT1080 tumors. In contrast, significantly lower ( p ≤ 0.01 ) 68Ga-NODAGA-c(NGR) accumulation was observed in both bestatin- and actinonin-treated B16-F10 melanoma tumors compared to the untreated-control tumors. Bestatin inhibited tumor growth and 68Ga-NODAGA-c(NGR) uptake in both tumor models. Conclusion. The bestatin treatment is suitable for suppressing the neoangiogenic process and APN/CD13 expression of experimental HT1080 and B16-F10 tumors; furthermore, 68Ga-NODAGA-c(NGR) is an applicable radiotracer for the in vivo monitoring of the efficacy of the APN/CD13 inhibition-based anticancer therapies.


2020 ◽  
Vol 58 ◽  
pp. 101798
Author(s):  
Madhan Mohan Chandra Sekhar Jaggarapu ◽  
Hari Krishnareddy Rachamalla ◽  
Narendra Varma Nimmu ◽  
Rajkumar Banerjee

2020 ◽  
Vol 66 (6) ◽  
pp. 464-468
Author(s):  
L.V. Kostryukova ◽  
Y.A. Tereshkina ◽  
E.I. Korotkevich ◽  
V.N. Prozorovsky ◽  
T.I. Torkhovskaya ◽  
...  

Doxorubicin is one of the widely known and frequently used chemotherapy drugs for the treatment of various types of cancer, the use of which is difficult due to its high cardiotoxicity. Targeted drug delivery systems are being developed to reduce side effects. One of the promising components as vector molecules (ligands) are NGR-containing peptides that are affinity for the CD13 receptor, which is expressed on the surface of many tumor cells and tumor blood vessels. Previously, a method was developed for preparing a composition of doxorubicin embedded in phospholipid nanoparticles with a targeted fragment in the form of an ultrafine emulsion. The resulting composition was characterized by a small particle size (less than 40 nm) and a high degree of incorporation of doxorubicin (about 93%) into transport nanoparticles. When assessing the penetrating ability and the degree of binding to the surface of fibrosarcoma cells (HT-1080), it was shown that when the composition with the targeted fragment was added to the cells, the level of doxorubicin was almost 2 times higher than that of the liposomal form of doxorubicin, i.e. the drug in the system with the targeted peptide penetrated the cell better. At the same time, on the control line of breast adenocarcinoma cells (MCF-7), which do not express the CD13 receptor on the surface, there was not significant difference in the level of doxorubicin in the cells. The data obtained allow us to draw preliminary conclusions about the prospects of targeted delivery of doxorubicin to tumor cells when using a peptide conjugate containing an NGR motif and the further need for its comprehensive study.


Molecules ◽  
2014 ◽  
Vol 19 (8) ◽  
pp. 11600-11612 ◽  
Author(s):  
Yahui Shao ◽  
Wansheng Liang ◽  
Fei Kang ◽  
Weidong Yang ◽  
Xiaowei Ma ◽  
...  

Amino Acids ◽  
2013 ◽  
Vol 44 (5) ◽  
pp. 1337-1345 ◽  
Author(s):  
Wenhui Ma ◽  
Fei Kang ◽  
Zhe Wang ◽  
Weidong Yang ◽  
Guiyu Li ◽  
...  

2012 ◽  
Vol 10 (1) ◽  
pp. 417-427 ◽  
Author(s):  
Kai Chen ◽  
Wenhui Ma ◽  
Guoquan Li ◽  
Jing Wang ◽  
Weidong Yang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document